Journal
CHEMISTRYSELECT
Volume 4, Issue 31, Pages 9040-9044Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/slct.201901293
Keywords
antitumor agents; clinical trials; inhibitors; protein kinase B
Categories
Funding
- Key Research and Development Program of Shandong Province [2017CXGC1401]
Ask authors/readers for more resources
The serine/threonine kinase Akt, also known as protein kinase B (PKB), exerts a critical role in the phosphoinositide 3-kinase (PI3 K)-Akt signaling pathway that involves in cell growth, proliferation, apoptosis and neo-angiogenesis. Inhibition of Akt results in blockade of cell-cycle progression and growth of tumors. Therefore, focusing on the drug design strategies to develop potent antitumor agents targeting Akt has been hot spot research areas. In this review, we summarized the intracellular functions of Akt, and outlined the development of Akt inhibitors in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available